- Home
- JUNS vs BOLT Comparison
JUNS vs BOLT Comparison
Compare JUNS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- BOLT
- Stock Information
- Founded
- JUNS 2015
- BOLT 2015
- Country
- JUNS United States
- BOLT United States
- Employees
- JUNS N/A
- BOLT N/A
- Industry
- JUNS
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- JUNS
- BOLT Health Care
- Exchange
- JUNS NYSE
- BOLT Nasdaq
- Market Cap
- JUNS 17.6M
- BOLT 16.8M
- IPO Year
- JUNS 2024
- BOLT 2021
- Fundamental
- Price
- JUNS $0.62
- BOLT $0.35
- Analyst Decision
- JUNS
- BOLT Hold
- Analyst Count
- JUNS 0
- BOLT 5
- Target Price
- JUNS N/A
- BOLT $1.13
- AVG Volume (30 Days)
- JUNS 146.8K
- BOLT 163.3K
- Earning Date
- JUNS 05-11-2025
- BOLT 05-13-2025
- Dividend Yield
- JUNS N/A
- BOLT N/A
- EPS Growth
- JUNS N/A
- BOLT N/A
- EPS
- JUNS N/A
- BOLT N/A
- Revenue
- JUNS N/A
- BOLT $7,690,000.00
- Revenue This Year
- JUNS N/A
- BOLT N/A
- Revenue Next Year
- JUNS N/A
- BOLT $77.45
- P/E Ratio
- JUNS N/A
- BOLT N/A
- Revenue Growth
- JUNS N/A
- BOLT N/A
- 52 Week Low
- JUNS $0.51
- BOLT $0.30
- 52 Week High
- JUNS $19.51
- BOLT $1.34
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- BOLT 42.86
- Support Level
- JUNS N/A
- BOLT $0.33
- Resistance Level
- JUNS N/A
- BOLT $0.39
- Average True Range (ATR)
- JUNS 0.00
- BOLT 0.04
- MACD
- JUNS 0.00
- BOLT -0.00
- Stochastic Oscillator
- JUNS 0.00
- BOLT 32.26
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.